ODAC to review Cell Therapeutics' NDA for pixantrone

[News]

Cell Therapeutics, Inc. (CTI) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).

More... (http://www.news-medical.net/news/20091217/ODAC-to-review-Cell-Therapeutics-NDA-for-pixantrone.aspx)